Navigation Links
NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
Date:11/16/2009

is now poised to bring its lead product to patients and physicians. In addition, we continue to apply our knowledge and expertise in the development of other novel treatments for pain.

Our lead product, Qutenza(TM) (capsaicin) 8% patch, is a dermal delivery system containing a prescription strength of capsaicin that is currently approved in the United States and the European Union. Qutenza is expected to be launched by NeurogesX in the United States in the first half of 2010. In Europe, Qutenza will be marketed by Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc.

NeurogesX's second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies.

NeurogesX's early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements about the safety and efficacy of Qutenza(TM); the timing of launch and commercialization of Qutenza; and NeurogesX' plans to commercialize Qutenza with its own sales force. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limite
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NeurogesX Expands Commercial Operations Leadership Team
2. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
3. NeurogesX to Present at JMP Securities Healthcare Focus Conference
4. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
5. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
6. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
7. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
8. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
9. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
10. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
11. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 Ultrasound devices enable physicians ... order to diagnose diseases and also these devices ... while performing surgeries. This report studies the global ... as product type, technologies, applications and the major ... on the product type has been segmented as: ...
(Date:9/23/2014)... 2014   LabStyle Innovations Corp . (OTCQB: ... today announced that it has closed a $4.2 ... preferred stock and warrants.  No placement agent was ... LabStyle expects to secure net proceeds of approximately ... LabStyle intends to use the net proceeds from ...
(Date:9/23/2014)... 2014 Report Details Kinase ... R&D and predicted revenues Do you want to ... the latest analysis for those cancer treatments. There ... revenue forecasts. Visiongain,s new report shows you ... and related technology. There avoid missing out in ...
Breaking Medicine Technology:Ultrasound Devices Market (By Product Type, By Technology and By Application - Obstetrics and Gynecology, Cardiovascular, Abdominal and Others) - Global Industry Analysis, Size, Share, Growth, Trends & Forecast, 2013 - 2019 2Ultrasound Devices Market (By Product Type, By Technology and By Application - Obstetrics and Gynecology, Cardiovascular, Abdominal and Others) - Global Industry Analysis, Size, Share, Growth, Trends & Forecast, 2013 - 2019 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 2LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 4LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 5Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 2Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 4Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 5
... MENLO PARK, Calif. , July 12 Crux Biomedical® ... of medical device and diagnostic companies. The survey, conducted by Medical Device ... issue. The purpose of the survey was to identify firms that have ... their respective products. , , ...
... OKLAHOMA CITY , July 12 For the second consecutive ... receive its prestigious R&D 100 Award.  Orthocare Innovations received this award for ... function of persons who have experienced lower limb loss, injury or disease. ... (Logo:   http://photos.prnewswire.com/prnh/20100712/DA33752LOGO ) ...
Cached Medicine Technology:Crux Biomedical Named One of Top 50 Companies to Watch 2Orthocare Innovations Receives Prestigious R&D 100 Award for Novel Web-Based Rehabilitation Outcomes Assessment System 2
(Date:9/23/2014)... first year follow a set of predictable steps ... first words. However, previous research had not addressed ... hearing and deaf infants. Now, University of Missouri ... by infants, ability to hear their own babbling. ... cochlear implants to help correct their hearing soon ...
(Date:9/23/2014)... University of California, Davis, and Academia Sinica, the ... (Taiwan), have entered into a collaborative agreement to ... that couples cutting-edge research with opportunities to translate ... companies. , The agreement was signed Sept.12 in ... at UC Davis and President Chi-Huey Wong of ...
(Date:9/23/2014)... Dallas, TX (PRWEB) September 23, 2014 Dr. ... of her medical practices to new office space at 12200 ... 29. Located at the office will be Park Cities Aesthetics, ... , In announcing her move, Dr. Casad said, ... of what treatment they select, we want them to always ...
(Date:9/23/2014)... rapidly developing, bringing with its advances promises of ... and treatment interventions. Genetic tests are already ... and hepatitis c virus (HPC), and emerging research ... screen for an individual,s susceptibility to addiction to ... , While there appear to be many benefits ...
(Date:9/23/2014)... Sept. 23, 2014 (HealthDay News) -- Few ... also undergo behavioral therapy, and the rates vary ... new study finds. Medication alone can manage ... do better if they also receive behavioral therapy ... researchers analyzed data in more than 1,500 counties ...
Breaking Medicine News(10 mins):Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2Health News:Dr. Connie Casad Moving to New Office Location 2Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2
... Reporter , TUESDAY, May 15 (HealthDay News) -- With the ... new study on air quality during the 2008 Beijing Olympics ... could lower the risk of heart trouble for many. ... advantage of changes in air quality surrounding the 2008 Olympics, ...
... , TUESDAY, May 15 (HealthDay News) -- The ... were saved between 2004 and 2008 by the U.S. President,s ... The program reduced adults, risk of death from all causes ... Stanford University School of Medicine researchers found. The researchers said ...
... An increasingly common and safer type of surgery for kidney ... sicker and poorer patients who are uninsured or rely on ... new study by researchers at Henry Ford Hospital. The ... portion of a cancerous kidney, leaving the unaffected part to ...
... better mousetrap, a team of Rice University freshmen took a ... children in the developing world. "The goal was to ... could prevent over-hydration and under-hydration," said Melissa Yuan, a member ... a mechanical engineering major. "It,s designed to be used in ...
... Although people with a family history of high blood pressure ... themselves, regular exercise and physical fitness may significantly lower that ... of this study send a very practical message, which is ... which we define as brisk walking for 150 minutes per ...
... Hospital (MGH) researchers suggests that specific populations of tumor cells ... new copies of themselves and grow. In their report ... researchers identify a tumor-propagating cell required for the growth of ... show that another, more-differentiated tumor cell must first travel to ...
Cached Medicine News:Health News:Beijing's Olympic Smog Shows Pollution's Effect on Health 2Health News:Beijing's Olympic Smog Shows Pollution's Effect on Health 3Health News:Safer kidney cancer surgery under-used for poorer, sicker Medicare, Medicaid patients 2Health News:This 'mousetrap' may save lives 2Health News:Fitness Fights High Blood Pressure, Even With Family History 2Health News:All cancer cells are not created equal 2Health News:All cancer cells are not created equal 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: